TABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Year: 2024
Type: other
Abstract: Cox proportional hazards model results for PFS and OS. Each row reflects a model with that variable; models across all patients are stratified on treatment arm. Baseline HCV only includes those with pretreatment HCV titer data available (n = 43), and first sample HCV includes baseline HCV titer data for those with it available and cycle 2 data for those missing baseline (n = 53)
Authors: Ghassan K. Abou-Alfa, Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Priya Kumthekar, Sawyer Jacobson, Imane El Dika, Amin Yaqubie, Juan Lopez, Binhui Huang, Yi-Wei Tang, Yujia Wen, Lawrence H. Schwartz, Anthony B. El-Khoueiry, Jennifer J. Knox, Lakshmi Rajdev, Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Alan P. Venook
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392561995